We are happy to announce that on July 30, 2019, the Food and Drug Administration (FDA) approved a new drug, darolutamide (NUBEQA®, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of men with non-metastatic castration-resistant prostate cancer.
Darolutamide - Great Results From The ARAMIS Trial For Men With M0 Prostate Cancer
The ARAMIS Trial showed that darolutamide increased overall survival for men with prostate cancer, it delayed the time to the use of cytotoxic chemotherapy as well as improving the important quality of life (QoL) measures of time to pain progression, and time to developing a symptomatic skeletal-related event.
ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
At the recent ASCO GU conference, we learned the results from the ARAMUS phase III trial which evaluated Darolutamide, an androgen receptor (AR) antagonist (a drug that prevents androgens from affecting prostate and prostate cancer cells). The trial studied the efficacy and safety of darolutamide in men with nmCRPC men.
ARAMIS Trial Finds That the Investigational Treatment Darolutamide Extends Metastasis-free Survival of Men with M0 Castrate Resistant Prostate Cancer
It has been announced that the Phase III ARAMIS Trial (Androgen Receptor inhibiting Agent for Metastatic-free Survival) evaluating an investigational treatment known as darolutamide in men with Non-metastatic Castration-resistant Prostate Cancer (nM0) has successfully met its primary endpoint of extending the metastasis-free survival (MFS) of men compared to placebo.
